vivi
Lv7
3950 积分
2022-09-16 加入
-
2016中国痛风诊疗指南
9天前
已完结
-
2016中国痛风诊疗指南
9天前
已关闭
-
Effect of Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of SHR4640, a Selective Human Urate Transporter 1 Inhibitor
13天前
已完结
-
Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study
1个月前
已完结
-
Prohormone cleavage prediction uncovers a non-incretin anti-obesity peptide
1个月前
已完结
-
ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials
1个月前
已完结
-
Safety and efficacy of GLP-1/FGF21 dual agonist HEC88473 in MASLD and T2DM: A randomized, double-blind, placebo-controlled study
2个月前
已完结
-
Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial
2个月前
已完结
-
Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial
2个月前
已完结
-
The first report of leukocytoclastic vasculitis induced by once-weekly subcutaneous semaglutide
3个月前
已完结